To improve the therapeutic impact of CAR T in the treatment of glioblastomas, tandem CAR T cells targeting HER2 and IL13Rα2 [380] and trivalent CAR T cells targeting HER2, IL13Rα2, and Ephrin-A2 [381] have been developed to bypass the interpatient antigenic heterogeneity and to mitigate tumor antigen escape. This evidence concerns the gene ERBB2 and glioblastoma.